dc.contributor.author
Lambrecht, Joeri
dc.contributor.author
Porsch-Özçürümez, Mustafa
dc.contributor.author
Best, Jan
dc.contributor.author
Jost-Brinkmann, Fabian
dc.contributor.author
Roderburg, Christoph
dc.contributor.author
Demir, Münevver
dc.contributor.author
Tacke, Frank
dc.contributor.author
Mohr, Raphael
dc.date.accessioned
2021-11-04T12:24:09Z
dc.date.available
2021-11-04T12:24:09Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/32539
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-32263
dc.description.abstract
(1) Background: Surveillance of at-risk patients for hepatocellular carcinoma (HCC) is highly necessary, as curative treatment options are only feasible in early disease stages. However, to date, screening of patients with liver cirrhosis for HCC mostly relies on suboptimal ultrasound-mediated evaluation and alpha-fetoprotein (AFP) measurement. Therefore, we sought to develop a novel and blood-based scoring tool for the identification of early-stage HCC. (2) Methods: Serum samples from 267 patients with liver cirrhosis, including 122 patients with HCC and 145 without, were collected. Expression levels of soluble platelet-derived growth factor receptor beta (sPDGFRβ) and routine clinical parameters were evaluated, and then utilized in logistic regression analysis. (3) Results: We developed a novel serological scoring tool, the APAC score, consisting of the parameters age, sPDGFRβ, AFP, and creatinine, which identified patients with HCC in a cirrhotic population with an AUC of 0.9503, which was significantly better than the GALAD score (AUC: 0.9000, p = 0.0031). Moreover, the diagnostic accuracy of the APAC score was independent of disease etiology, including alcohol (AUC: 0.9317), viral infection (AUC: 0.9561), and NAFLD (AUC: 0.9545). For the detection of patients with (very) early (BCLC 0/A) HCC stage or within Milan criteria, the APAC score achieved an AUC of 0.9317 (sensitivity: 85.2%, specificity: 89.2%) and 0.9488 (sensitivity: 91.1%, specificity 85.3%), respectively. (4) Conclusions: The APAC score is a novel and highly accurate serological tool for the identification of HCC, especially for early stages. It is superior to the currently proposed blood-based algorithms, and has the potential to improve surveillance of the at-risk population.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
liquid biopsy
en
dc.subject
liver cancer
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
3392
dcterms.bibliographicCitation.doi
10.3390/jcm10153392
dcterms.bibliographicCitation.journaltitle
Journal of Clinical Medicine
dcterms.bibliographicCitation.number
15
dcterms.bibliographicCitation.originalpublishername
MDPI AG
dcterms.bibliographicCitation.volume
10
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34362181
dcterms.isPartOf.eissn
2077-0383